Current Report Filing (8-k)
18 May 2017 - 1:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event
reported):
May 17,
2017
|
NEXUS BIOPHARMA, INC.
|
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
|
Nevada
|
|
000-53207
|
|
75-3267338
|
(State
or other jurisdiction
of
incorporation)
|
|
(CommissionFile
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
JLABS @ TMCx
2450 Holcombe Blvd., Suite J
Houston TX
|
|
77021
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's telephone number, including area
code:
(832)758-7488
_________________________________________
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
.
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐
.
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐
.
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐
.
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Nexus BioPharma, Inc.
(the “Company”) prepared an investor
presentation to be used in certain investor meetings, beginning May
17, 2017. The presentation included a power point presentation in
the form attached hereto as Exhibit 99.1.
This information is “furnished” and not
“filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, or otherwise subject to the liabilities of
that section. It may only be incorporated by reference in another
filing under the Securities Exchange Act of 1934 or the Securities
Act of 1933 only if and to the extent such subsequent filing
specifically references the information incorporated by reference
herein.
All statements in this report that do not directly and exclusively
relate to historical facts constitute “forward-looking
statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements represent the
Company’s intentions, plans, expectations and beliefs, and
are subject to risks, uncertainties and other factors many
of which are outside the Company’s control. These
factors could cause actual results to differ materially from such
forward-looking statements. For a written description of these
factors, see the section titled “Risk Factors” in the
Company’s Form 10-K for the fiscal year ended February 28,
2016 and any updating information in subsequent SEC
filings. The Company disclaims any intention or
obligation to update these forward-looking statements whether as a
result of subsequent event or otherwise, except as required by
law.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
NEXUS BIOPHARMA INC.
|
|
|
|
Date:
May 17, 2017
|
By:
|
/s/ Warren Lau
|
|
|
Warren
Lau
|
Exhibit Index
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
Investor
Presentation
|